Microdose GLP-1 and PCOS: Who Lower-Dose Protocols May Fit

Standard-dose GLP-1 protocols are calibrated for significant weight loss — the trial curves were designed to maximize body-weight reduction in patients with obesity. For PCOS patients with significant weight to lose, those protocols fit well. But not every PCOS patient has significant weight to lose, and not every PCOS patient should be on a protocol designed primarily for that goal.

Microdose GLP-1 protocols use lower weekly doses calibrated with the aim of supporting insulin sensitivity and cycle health while minimizing weight loss — whether that aim is achieved varies by patient and is evaluated by the prescribing clinician. For a subset of PCOS patients — particularly those with lean PCOS, those near their target weight, and those who have struggled with GI tolerability on standard doses — microdosing is one approach a clinician may consider. This post walks through who may fit a microdose protocol, how clinicians think about the dosing, and how monitoring works.

Why microdose at all in PCOS

PCOS is, in most cases, a metabolic condition first. Researchers attribute much of the cycle irregularity, androgen excess, and weight retention to insulin resistance. Studies report that when insulin resistance and weight improve, downstream symptoms often improve as well — though the degree varies from patient to patient.

For a patient with significant weight to lose, treating both arms — standard-dose GLP-1 plus lifestyle plus possibly metformin or inositol — is a common clinical approach. In clinical trials of the FDA-approved versions of these medications (not compounded preparations), participants receiving full-dose therapy lost on average roughly 15–22% of body weight; trial results describe study populations and do not predict individual outcomes.

But what about a PCOS patient who is already at a healthy BMI? Or a patient five or ten pounds above their target weight? Or a patient with severe GI intolerance to standard-dose titration?

For those patients, the standard-dose protocol is over-engineered. It is producing weight loss they do not need or do not want, at a side-effect cost they may not tolerate. Microdosing reverses the calculus: the dose is calibrated against the metabolic goal (insulin sensitivity, androgen reduction, cycle regularity) rather than the weight goal. The intent is to target metabolic endpoints rather than maximal weight loss; whether and to what degree a given patient's metabolic markers respond is individual, and the clinician monitors labs to find out.

This is not a hypothetical use case — it is a clinical reality for a meaningful fraction of PCOS patients seeking GLP-1 therapy. Microdose protocols are one way clinicians may offer this medication class to such patients when, in their individual judgment, it is appropriate.

Who fits a microdose protocol

There are four common candidate profiles for microdose GLP-1 in PCOS:

1. Lean PCOS. Approximately 20–30% of women with PCOS have what is sometimes called the "lean phenotype" — a normal BMI alongside biochemical hyperandrogenism and irregular cycles. The metabolic dysfunction is present (often as insulin resistance detectable on fasting insulin or HOMA-IR), but it is not accompanied by the weight that drives most PCOS care decisions. For these patients, standard-dose GLP-1 may produce weight loss they do not want. Microdose protocols are intended to pursue insulin-sensitivity goals while limiting weight reduction; direct evidence in lean PCOS is limited, and response varies by patient.

2. Near-target-weight patients with persistent PCOS symptoms. A patient who has gotten close to a healthy BMI through lifestyle intervention but whose cycles remain irregular and whose insulin markers are still elevated may benefit from a microdose GLP-1 protocol to push the metabolic improvements further. The goal here is not to lose another 15 pounds — it is to keep nudging the insulin axis in the right direction.

3. GI-sensitive patients. Some patients tolerate the standard titration curve poorly — persistent nausea, occasional vomiting, GI dysmotility that does not resolve with the standard escalation cadence. For these patients, the question is whether to discontinue GLP-1 entirely or to stay at a lower dose that the body tolerates. Microdose protocols are one option the clinician may consider.

4. Maintenance after standard-dose therapy. A patient who has used standard-dose GLP-1 to reach a target weight and improve metabolic markers may transition to a microdose protocol for long-term maintenance. The maintenance dose is lower than the loss-phase dose and is designed to prevent rebound while minimizing ongoing side-effect exposure. Recent maintenance trials in the general weight-loss population have validated this pattern; the PCOS-specific evidence is following.

What the dose actually looks like

Microdose GLP-1 in PCOS uses a fraction of the standard trial-curve dose. The specific dose is set by the prescribing clinician for each patient, but the general framework:

For compounded semaglutide, clinicians who use microdose approaches prescribe well below the standard escalation curve used for weight loss, with slower, more gradual dose increases.

For compounded tirzepatide, microdose plans likewise sit well below the standard escalation curve. Specific doses and titration timing are set by the prescribing clinician for each patient — they are not figures to self-select or self-adjust.

The escalation cadence is also gentler. Standard protocols escalate every four weeks toward a target dose. Microdose protocols stay at the same dose for longer, often eight weeks or more, while the clinician evaluates response on metabolic and cycle endpoints rather than scale change.

In every case, the clinician calibrates the actual dose to the individual patient based on weight, insulin markers, cycle history, and tolerance. The point is that microdose protocols are not just "lower" — they are calibrated against a different goal.

How monitoring works on a microdose protocol

Rather than a fixed timeline of expected results, here is how clinicians typically monitor response over time. Individual results vary and no particular outcome is guaranteed.

Weeks 1–4. Side effects are often milder at microdose levels than on standard-dose titration. Occasional nausea, mild appetite reduction, and slight GI changes can occur but are usually not pronounced. Weight may be stable or change slowly.

Weeks 4–12. This is typically when the clinician first re-checks metabolic labs (fasting insulin, HOMA-IR) to evaluate whether markers are responding. Response varies and is not guaranteed; the dose plan is adjusted based on what the labs show. Cycles may not have changed visibly yet — cycle changes, when they occur, typically take longer.

Months 3–6. This is the window in which the clinician evaluates cycle patterns and repeat labs. Some patients see changes in cycles, androgens (free testosterone, SHBG), or weight in this window; others do not — no particular outcome or amount of change can be promised, and the plan is adjusted individually.

Months 6–12. The clinician evaluates whether to maintain the microdose, adjust slightly up or down, or layer in other PCOS therapies (metformin, inositol) for the long term. Some microdose PCOS patients stay on the protocol as part of long-term PCOS management, when their clinician determines it remains appropriate.

Microdose versus other PCOS therapies

A reasonable question: if you have lean PCOS or are near a healthy BMI, why use GLP-1 at all instead of metformin or inositol?

The honest answer is: it depends on the patient. Some lean PCOS patients respond well to metformin and inositol alone and do not need GLP-1. Some respond partially and benefit from layering microdose GLP-1 on top. Some do not respond to metformin or inositol and need a different mechanism — GLP-1 acts on different pathways and produces different effects.

The decision is made individually. The microdose GLP-1 protocol exists as an option for PCOS patients who would benefit from the medication class but do not need or want the magnitude of weight loss that standard-dose protocols produce. It is not the first choice for every PCOS patient. It is the right choice for a meaningful subset.

How TelePeptide runs microdose PCOS protocols

Microdose protocols at TelePeptide use the same compounded medications as our standard PCOS protocol — semaglutide or tirzepatide, prepared by licensed 503A pharmacies under individual prescription. The difference is in the dose plan, the titration cadence, and the monitoring focus.

During intake, the clinician asks about weight goals, cycle history, insulin and androgen markers (if you have recent labs), and GI history. If your profile fits a microdose protocol, the clinician will lay out a dose plan that targets the metabolic and cycle improvements rather than significant weight loss. The pricing is the same as the standard protocol — the dose is a clinical decision, not a pricing tier.

For patients with TTC plans, the microdose protocol still requires the same washout windows as standard-dose protocols. The medication is the same; only the dose is different. If TTC is on your near-term horizon, that conversation happens at intake.

Compounded medications are not FDA-approved. GLP-1 use for PCOS is off-label, supported by the 2023 International Evidence-Based PCOS Guideline as an option for metabolic management.

What starting the protocol actually looks like (August 2026 update)

Since this article was first published, the intake flow has been shortened, and "how do I actually start?" is the question patients ask most — so here it is concretely:

1. A free online intake, about 5 minutes. Health questions only — no appointment to schedule, no payment required to be evaluated. The full step-by-step is here.
2. A licensed clinician reviews your intake individually. If the protocol isn't appropriate for you, they say so — and you pay nothing at all.
3. If prescribed, your medication ships in 3–5 days from a US-licensed pharmacy, with online follow-ups included.

Pricing is flat and published: the Microdose GLP-1 protocol is $149/month month-to-month, or $134/month billed annually — medication, clinician evaluation, follow-ups, and shipping included, no insurance involved. Your card is authorized at intake but charged only if a clinician prescribes. The current pricing for every program is here, and the intake itself starts at telepeptide.org/intake.

---

Disclaimer: This article is education, not medical advice. Compounded medications are not FDA-approved, and GLP-1 use for PCOS is off-label. Any treatment decision is made solely by a licensed clinician after an individualized evaluation. Individual results vary — no outcome is guaranteed. Whether microdose GLP-1 fits your PCOS picture is a clinical decision made with your prescribing clinician based on your individual profile.

---

Editorial note: TelePeptide (the company) is a US direct-pay telehealth practice offering clinician-supervised compounded peptide therapy in 48 US states + DC. The brand name is sometimes autocorrected to "telopeptide" — an unrelated collagen biomarker; the two terms have no clinical connection.